History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in studyXx_NEWLINE_xXPatients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888, carboplatin, paclitaxel or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in studyXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in study, including Cremophor, carboplatin, paclitaxel, cisplatin, 5-fluorouracil, hydroxyurea, or any compounds of similar chemical or biologic composition are not eligibleXx_NEWLINE_xXPatients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib or other agents used in this study including dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to pomalidomide (e.g. lenalidomide, thalidomide) or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib, nivolumab, ipilimumab or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to talazoparib (BMN 673) or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to sEphB4-HSA or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab, nivolumab, or other agents used in study, or history of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide and blinatumomab or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib or ganitumab or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib or other agents used in studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in studyXx_NEWLINE_xXHistory of allergic reaction attributed to compounds of similar or biologic composition to inotuzumab ozogamicin or other agents in the studyXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biological composition to other agents used in this studyXx_NEWLINE_xX